BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30535292)

  • 21. Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease.
    Chateau T; Angioi K; Peyrin-Biroulet L
    J Crohns Colitis; 2020 May; 14(4):571. PubMed ID: 31606743
    [No Abstract]   [Full Text] [Related]  

  • 22. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
    Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
    Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease.
    Al-Raddadi R; Frances C; Moguelet P; Bachmeyer C; Guégan S
    Acta Derm Venereol; 2017 Mar; 97(3):389-390. PubMed ID: 27722763
    [No Abstract]   [Full Text] [Related]  

  • 24. Pyoderma gangrenosum and tumor necrosis factor α agents.
    Rallis E; Koumantaki-Mathioudaki E; Tsiatoura A; Stavropoulos P; Katsambas A
    Cutis; 2013 Oct; 92(4):E1-2. PubMed ID: 24195097
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease.
    Madarame A; Kimura H; Kunisaki R
    J Crohns Colitis; 2020 May; 14(4):569-570. PubMed ID: 31616911
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
    Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
    Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scrotal pyoderma gangrenosum associated with Crohn's disease.
    Ho SA; Tan WP; Tan AW; Wong SN; Chua SH
    Singapore Med J; 2009 Dec; 50(12):e397-400. PubMed ID: 20087538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
    Bertrand V; El Haite A; Carré D
    Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
    López San Román A; Bermejo F; Aldanondo I; Carrera E; Boixeda D; Muñoz Zato E
    Rev Esp Enferm Dig; 2004 Jun; 96(6):420-2; 422-4. PubMed ID: 15230672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum.
    Greb JE; Gottlieb AB; Goldminz AM
    Dermatol Ther; 2016 Nov; 29(6):482-483. PubMed ID: 27502191
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
    Sapienza MS; Cohen S; Dimarino AJ
    Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
    Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
    United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn's disease.
    Carp JM; Onuma E; Das K; Gottlieb AB
    Cutis; 1997 Sep; 60(3):135-8. PubMed ID: 9314617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic Cutaneous Crohn's Disease of the Face-A Case Successfully Treated With Ustekinumab.
    Martins Figueiredo L; Oliveira AM; Martins A
    J Crohns Colitis; 2020 Jul; 14(6):874-875. PubMed ID: 31630151
    [No Abstract]   [Full Text] [Related]  

  • 36. Successful Therapy of Crohn's Disease-Associated Pulmonary Necrobiotic Nodules on Ustekinumab Therapy.
    Ganzleben I; Hirschmann S; Köhler J; Fuchs FS; Rieker RJ; Baer E; Klenske E; Nagore D; Neurath MF; Atreya R
    Am J Gastroenterol; 2020 Apr; 115(4):632-634. PubMed ID: 32149778
    [No Abstract]   [Full Text] [Related]  

  • 37. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ustekinumab for the treatment of Crohn's disease -Indication of Ustekinumab according to efficacy and safety].
    Ishihara S; Kawashima K; Kinoshita Y
    Nihon Shokakibyo Gakkai Zasshi; 2019; 116(3):216-223. PubMed ID: 30853674
    [No Abstract]   [Full Text] [Related]  

  • 39. Bullous pyoderma gangrenosum secondary to underlying multiple myeloma: treated with ciclosporin.
    Razmi T M; Muhammed H; Handa S; Malhotra P; Sharma S; Saikia UN; Aggarwal R; Dogra S
    Clin Exp Dermatol; 2019 Mar; 44(2):e13-e15. PubMed ID: 30294832
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pyoderma gangrenosum associated with Crohn's disease].
    Mikić D; Bojić I; Zecević R; Marinković V; Lukacević S
    Vojnosanit Pregl; 1995; 52(5):505-8. PubMed ID: 8545995
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.